Specifically, we plan: 
1) To establish a safe and effective dose to introduce a 
recombinant HLA-B7 gene into tumors by DNA/ liposome- 
mediated transfection in living human subjects. 
2) To confirm expression of this class I MHC gene introduced 
directly into tumor cells in vivo . 
3) To analyze the specificity of the immune response against 
this antigen in vivo by analyzing cellular and humoral 
immunity. 
[404] 
Recombinant DNA Research, Volume 15 
